Literature DB >> 22787435

A requirement for SOCS-1 and SOCS-3 phosphorylation in Bcr-Abl-induced tumorigenesis.

Xiaoxue Qiu1, Guijie Guo, Ke Chen, Masaki Kashiwada, Brian J Druker, Paul B Rothman, Ji-Long Chen.   

Abstract

Suppressors of cytokine signaling 1 and 3 (SOCS-1 and SOCS-3) are inhibitors of the Janus tyrosine kinase (JAK)/signal transducers and activators of transcription (STAT) pathway and function in a negative feedback loop during cytokine signaling. Abl transformation is associated with constitutive activation of JAK/STAT-dependent signaling. However, the mechanism by which Abl oncoproteins bypass SOCS inhibitory regulation remains poorly defined. Here, we demonstrate that coexpression of Bcr-Abl with SOCS-1 or SOCS-3 results in tyrosine phosphorylation of these SOCS proteins. Interestingly, SOCS-1 is highly tyrosine phosphorylated in one of five primary chronic myelogenous leukemia samples. Bcr-Abl-dependent tyrosine phosphorylation of SOCS-1 and SOCS-3 occurs mainly on Tyr 155 and Tyr 204 residues of SOCS-1 and on Tyr 221 residue of SOCS-3. We observed that phosphorylation of these SOCS proteins was associated with their binding to Bcr-Abl. Bcr-Abl-dependent phosphorylation of SOCS-1 and SOCS-3 diminished their inhibitory effects on the activation of JAK and STAT5 and thereby enhanced JAK/STAT5 signaling. Strikingly, disrupting the tyrosine phosphorylation of SOCS-1 or SOCS-3 impaired the expression of Bcl-X(L) protein and sensitized K562 leukemic cells to undergo apoptosis. Moreover, selective mutation of tyrosine phosphorylation sites of SOCS-1 or SOCS-3 significantly blocked Bcr-Abl-mediated tumorigenesis in nude mice and inhibited Bcr-Abl-mediated murine bone marrow transformation. Together, these results reveal a mechanism of how Bcr-Abl may overcome SOCS-1 and SOCS-3 inhibition to constitutively activate the JAK/STAT-dependent signaling, and suggest that Bcr-Abl may critically requires tyrosine phosphorylation of SOCS-1 and SOCS-3 to mediate tumorigenesis when these SOCS proteins are present in cells.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22787435      PMCID: PMC3394197          DOI: 10.1596/neo.12230

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  47 in total

1.  Somatic hypermutation of SOCS1 in lymphocyte-predominant Hodgkin lymphoma is accompanied by high JAK2 expression and activation of STAT6.

Authors:  Anja Mottok; Christoph Renné; Klaus Willenbrock; Martin-Leo Hansmann; Andreas Bräuninger
Journal:  Blood       Date:  2007-07-25       Impact factor: 22.113

2.  Both the suppressor of cytokine signaling 1 (SOCS-1) kinase inhibitory region and SOCS-1 mimetic bind to JAK2 autophosphorylation site: implications for the development of a SOCS-1 antagonist.

Authors:  Lilian W Waiboci; Chulbul M Ahmed; Mustafa G Mujtaba; Lawrence O Flowers; James P Martin; Mohammed I Haider; Howard M Johnson
Journal:  J Immunol       Date:  2007-04-15       Impact factor: 5.422

3.  The myeloproliferative disorder-associated JAK2 V617F mutant escapes negative regulation by suppressor of cytokine signaling 3.

Authors:  Michelle B Hookham; Joanne Elliott; Yvonne Suessmuth; Judith Staerk; Alister C Ward; William Vainchenker; Melanie J Percy; Mary Frances McMullin; Stefan N Constantinescu; James A Johnston
Journal:  Blood       Date:  2007-02-22       Impact factor: 22.113

Review 4.  The JAK-STAT signaling pathway: input and output integration.

Authors:  Peter J Murray
Journal:  J Immunol       Date:  2007-03-01       Impact factor: 5.422

5.  The SOCS-1 gene methylation in chronic myeloid leukemia patients.

Authors:  Ozden Hatirnaz; Umit Ure; Cem Ar; Cemaliye Akyerli; Teoman Soysal; Burhan Ferhanoğlu; Tayfun Ozçelik; Ugur Ozbek
Journal:  Am J Hematol       Date:  2007-08       Impact factor: 10.047

6.  Dormant tumor cells develop cross-resistance to apoptosis induced by CTLs or imatinib mesylate via methylation of suppressor of cytokine signaling 1.

Authors:  Aurore Saudemont; Abdelbasset Hamrouni; Philippe Marchetti; Jizhong Liu; Nathalie Jouy; Dominique Hetuin; Francesco Colucci; Bruno Quesnel
Journal:  Cancer Res       Date:  2007-05-01       Impact factor: 12.701

7.  Bruton's tyrosine kinase is not essential for Bcr-Abl-mediated transformation of lymphoid or myeloid cells.

Authors:  M MacPartlin; A M Smith; B J Druker; L A Honigberg; M W Deininger
Journal:  Leukemia       Date:  2008-06-12       Impact factor: 11.528

8.  Pim-1 and Pim-2 kinases are required for efficient pre-B-cell transformation by v-Abl oncogene.

Authors:  Ji-Long Chen; Andre Limnander; Paul B Rothman
Journal:  Blood       Date:  2007-11-27       Impact factor: 22.113

Review 9.  SOCS proteins, cytokine signalling and immune regulation.

Authors:  Akihiko Yoshimura; Tetsuji Naka; Masato Kubo
Journal:  Nat Rev Immunol       Date:  2007-05-18       Impact factor: 53.106

Review 10.  Oncogenic signaling: new insights and controversies from chronic myeloid leukemia.

Authors:  Richard A Van Etten
Journal:  J Exp Med       Date:  2007-03-12       Impact factor: 14.307

View more
  19 in total

1.  Cancer subclonal genetic architecture as a key to personalized medicine.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2013-12       Impact factor: 5.715

Review 2.  STAT transcription factors in hematopoiesis and leukemogenesis: opportunities for therapeutic intervention.

Authors:  K A Dorritie; J A McCubrey; D E Johnson
Journal:  Leukemia       Date:  2013-06-25       Impact factor: 11.528

3.  Bortezomib induces apoptosis by interacting with JAK/STAT pathway in K562 leukemic cells.

Authors:  Nur Selvi; Burçin Tezcanli Kaymaz; Cumhur Gündüz; Cağdaş Aktan; Hatice Demet Kiper; Fahri Sahin; Melda Cömert; Ali Fatih Selvi; Buket Kosova; Güray Saydam
Journal:  Tumour Biol       Date:  2014-05-14

4.  Overcoming intratumor heterogeneity of polygenic cancer drug resistance with improved biomarker integration.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2012-12       Impact factor: 5.715

Review 5.  The role of suppressors of cytokine signalling in human neoplasms.

Authors:  Walid Sasi; Anup K Sharma; Kefah Mokbel
Journal:  Mol Biol Int       Date:  2014-03-16

6.  Suppression of interferon lambda signaling by SOCS-1 results in their excessive production during influenza virus infection.

Authors:  Haitao Wei; Song Wang; Qinghuang Chen; Yuhai Chen; Xiaojuan Chi; Lianfeng Zhang; Shile Huang; George F Gao; Ji-Long Chen
Journal:  PLoS Pathog       Date:  2014-01-02       Impact factor: 6.823

7.  A critical role of CDKN3 in Bcr-Abl-mediated tumorigenesis.

Authors:  Qinghuang Chen; Ke Chen; Guijie Guo; Fang Li; Chao Chen; Song Wang; Grzegorz Nalepa; Shile Huang; Ji-Long Chen
Journal:  PLoS One       Date:  2014-10-31       Impact factor: 3.240

8.  A long noncoding RNA critically regulates Bcr-Abl-mediated cellular transformation by acting as a competitive endogenous RNA.

Authors:  G Guo; Q Kang; X Zhu; Q Chen; X Wang; Y Chen; J Ouyang; L Zhang; H Tan; R Chen; S Huang; J-L Chen
Journal:  Oncogene       Date:  2014-05-19       Impact factor: 9.867

Review 9.  Understanding and targeting cancer stem cells: therapeutic implications and challenges.

Authors:  Ke Chen; Ying-hui Huang; Ji-long Chen
Journal:  Acta Pharmacol Sin       Date:  2013-05-20       Impact factor: 6.150

10.  eIF4B is a convergent target and critical effector of oncogenic Pim and PI3K/Akt/mTOR signaling pathways in Abl transformants.

Authors:  Ke Chen; Jianling Yang; Jianning Li; Xuefei Wang; Yuhai Chen; Shile Huang; Ji-Long Chen
Journal:  Oncotarget       Date:  2016-03-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.